(Q51900295)

17 April 2018

title

DNA Damage and Repair in Translational Oncology: An Overview (English)

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

8 July 2024

author name string

Eddie Reed

1

1 reference

17 April 2018

language of work or name

English

0 references

publication date

7 September 2010

1 reference

17 April 2018

full work available at URL

http://clincancerres.aacrjournals.org/content/16/18/4511.full.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20823144

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/18/4511

8 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20823144

https://aacrjournals.org/clincancerres/article-pdf/16/18/4511/1992378/4511.pdf

8 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

8 July 2024

published in

Clinical Cancer Research

1 reference

17 April 2018

volume

16

1 reference

17 April 2018

issue

18

1 reference

17 April 2018

page(s)

4511-4516

1 reference

17 April 2018

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer

cites work

3

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

8 July 2024

4

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

8 July 2024

5

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Epigenetic modifications in double-strand break DNA damage signaling and repair

8 July 2024

6

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

8 July 2024

7

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

8 July 2024

8

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

8 July 2024

9

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

DNA Damage, Aging, and Cancer

8 July 2024

11

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

The DNA-damage response in human biology and disease

8 July 2024

12

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity

8 July 2024

13

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

8 July 2024

14

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

ERCC1 measurements in clinical oncology

8 July 2024

15

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Molecular cloning of a human DNA repair gene

8 July 2024

16

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

ERCC1-XPF endonuclease facilitates DNA double-strand break repair

8 July 2024

17

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

8 July 2024

18

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

8 July 2024

20

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

8 July 2024

22

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

ERCC1 and clinical resistance to platinum-based therapy

8 July 2024

23

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature

8 July 2024

24

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer

8 July 2024

25

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer

8 July 2024

26

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy

8 July 2024

27

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy

8 July 2024

28

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.

8 July 2024

29

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.

8 July 2024

30

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells.

8 July 2024

32

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines

8 July 2024

34

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

MZF1 possesses a repressively regulatory function in ERCC1 expression

8 July 2024

35

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Loss of heterozygosity in human ovarian cancer on chromosome 19q.

8 July 2024

38

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

8 July 2024

40

1 reference

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0528

8 July 2024

Identifiers

1 reference

17 April 2018

1 reference

17 April 2018